Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$23.10−0.20 (-0.86%)
Close on Nov 17, 2026Market cap $462.26MP/E –Yield –
Neurogene r&d expenses
Research and development expenses are spending on new products and technology.
Neurogene's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.50M, up 28.7% year over year. For fiscal 2025 it was $75.01M, up 23.1% from the year before. Over ten years it grew 16.9% a year on average. The highest annual figure on record is $75.01M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.01M | +23.1% |
| FY2024 | Dec 31, 2024 | $60.92M | +37.2% |
| FY2023 | Dec 31, 2023 | $44.39M | -6.5% |
| FY2022 | Dec 31, 2022 | $47.51M | +21.3% |
| FY2021 | Dec 31, 2021 | $39.16M | +60.9% |
| FY2020 | Dec 31, 2020 | $24.34M | +451.1% |
| FY2019 | Dec 31, 2019 | $4.42M | -89.4% |
| FY2018 | Dec 31, 2018 | $41.79M | +15.2% |
| FY2017 | Dec 31, 2017 | $36.27M | +27.8% |
| FY2016 | Dec 31, 2016 | $28.38M | +79.6% |
| FY2015 | Dec 31, 2015 | $15.80M | -12.6% |
| FY2014 | Dec 31, 2014 | $18.08M | +137.9% |
| FY2013 | Dec 31, 2013 | $7.60M | +25.7% |
| FY2012 | Dec 31, 2012 | $6.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $25.47M | +31.5% |
| Q1 FY2026 | Mar 31, 2026 | $25.15M | +41.6% |
| Q4 FY2025 | Dec 31, 2025 | $20.64M | +34.5% |
| Q3 FY2025 | Sep 30, 2025 | $17.24M | +5.9% |
| Q2 FY2025 | Jun 30, 2025 | $19.37M | +23.0% |
| Q1 FY2025 | Mar 31, 2025 | $17.76M | +31.2% |
| Q4 FY2024 | Dec 31, 2024 | $15.35M | +26.0% |
| Q3 FY2024 | Sep 30, 2024 | $16.29M | +40.3% |
| Q2 FY2024 | Jun 30, 2024 | $15.74M | +52.5% |
| Q1 FY2024 | Mar 31, 2024 | $13.54M | +31.7% |
| Q4 FY2023 | Dec 31, 2023 | $12.18M | -25.6% |
| Q3 FY2023 | Sep 30, 2023 | $11.61M | +22.5% |
| Q2 FY2023 | Jun 30, 2023 | $10.32M | -5.8% |
| Q1 FY2023 | Mar 31, 2023 | $10.28M | -3.9% |
| Q4 FY2022 | Dec 31, 2022 | $16.38M | +67.8% |
| Q3 FY2022 | Sep 30, 2022 | $9.47M | -4.3% |
| Q2 FY2022 | Jun 30, 2022 | $10.96M | +11.5% |
| Q1 FY2022 | Mar 31, 2022 | $10.70M | +10.2% |
| Q4 FY2021 | Dec 31, 2021 | $9.76M | +25.3% |
| Q3 FY2021 | Sep 30, 2021 | $9.90M | +59.2% |
| Q2 FY2021 | Jun 30, 2021 | $9.82M | +102.8% |
| Q1 FY2021 | Mar 31, 2021 | $9.71M | +76.6% |
| Q4 FY2020 | Dec 31, 2020 | $7.79M | +7387.5% |
| Q3 FY2020 | Sep 30, 2020 | $6.22M | +141.7% |
| Q2 FY2020 | Jun 30, 2020 | $4.84M | -54.8% |
| Q1 FY2020 | Mar 31, 2020 | $5.50M | -69.4% |
| Q1 FY2019 | Mar 31, 2019 | $104.00K | -99.0% |
| Q4 FY2018 | Dec 31, 2018 | $2.57M | -77.7% |
| Q3 FY2018 | Sep 30, 2018 | $10.71M | +26.7% |
| Q2 FY2018 | Jun 30, 2018 | $18.00M | +71.8% |
| Q1 FY2018 | Mar 31, 2018 | $10.51M | +81.9% |
| Q4 FY2017 | Dec 31, 2017 | $11.56M | +42.1% |
| Q3 FY2017 | Sep 30, 2017 | $8.46M | +37.9% |
| Q2 FY2017 | Jun 30, 2017 | $10.48M | – |
| Q1 FY2017 | Mar 31, 2017 | $5.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.13M | – |
| Q3 FY2016 | Sep 30, 2016 | $6.13M | – |
See a number that looks wrong?